FIELD: medicine.
SUBSTANCE: device has film manufactured from polyacryl amide copolymer saturated with Cyclosporine A. Its concentration is approximately equal to 0.3-0.6 mg per 1 mm2.
EFFECT: enhanced effectiveness of treatment with strong immunosuppressive and anti-inflammatory effect; reduced risk of adverse side effects.
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR TREATING THE CASES OF DRY EYE SYNDROME | 2005 |
|
RU2290923C2 |
METHOD OF TREATING DRY EYE SYNDROME | 2015 |
|
RU2581495C1 |
METHOD OF TREATING INFLAMMATIONS OF ANTERIOR EYE SEGMENT | 2013 |
|
RU2513597C1 |
GEL-LIKE ARTIFICIAL TEARS WITH ANTISEPTIC AND REPARATIVE ACTION | 2018 |
|
RU2679319C1 |
AGENT FOR TREATMENT OF DRY EYE SYNDROME AS COMPLICATION AFTER OPHTHALMIC INFECTION | 2003 |
|
RU2239436C1 |
METHOD FOR TREATMENT OF HEAVY FORMS OF DRY KERATOCONJUNCTIVITIS | 2016 |
|
RU2621553C1 |
METHOD FOR CHOOSING PATHOGENETICALLY CAUSED THERAPEUTIC APPROACH TO VIRAL OCULAR DISEASES | 2012 |
|
RU2494741C1 |
PHARMACEUTICAL COMPOSITION IN FORM OF GEL-LIKE OPHTHALMIC DROPS FOR TREATING GLAUCOMA | 2015 |
|
RU2576778C1 |
DIAGNOSTIC TECHNIQUE AND METHOD OF THERAPY OF DRUG-INDUCED DRY EYE SYNDROME | 2014 |
|
RU2554818C1 |
METHOD OF TREATING BLEPHAROCONJUNCTIVAL FORM OF DRY EYE SYNDROME | 2012 |
|
RU2510701C1 |
Authors
Dates
2006-10-20—Published
2004-10-13—Filed